Shares of Amgen AMGN were unchanged after the company reported Q3 results.
Quarterly Results
Earnings per share increased 19.40% over the past year to $4.37, which beat the estimate of $3.80.
Revenue of $6,423,000,000 rose by 11.96% year over year, which beat the estimate of $6,350,000,000.
Outlook
Amgen Narrows FY20 Sales Guidance To $25.1B-$25.5B vs $25.41B Estimate, Adj. EPS $15.80-$16.15 vs $15.77 Est.
Conference Call Details
Date: Oct 28, 2020
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/kjjwpzrp
Recent Stock Performance
Company's 52-week high was at $264.97
Company's 52-week low was at $177.05
Price action over last quarter: down 12.51%
Company Overview
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
